Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

5 Sept 2019

Abstract excerpt

BACKGROUND: A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31562764
DOI: 10.1093/annonc/mdz390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancerPMID 31562764Read ↗

Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancerSemantic proximity Read ↗

Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancerSemantic proximity Read ↗

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)Semantic proximity Read ↗

Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.Semantic proximity Read ↗

Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsySemantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity Read ↗

Circulating tumor DNA in colorectal cancer: biology, methods and applicationsSemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.Semantic proximity Read ↗

Minimal residual disease detection with circulating tumor DNA in colorectal cancer: current horizons and future perspectives in clinical applicationsSemantic proximity Read ↗

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity Read ↗

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.